Summary We have investigated the inhibitory effect on experimental or spontaneous lung metastases of polypeptides which contain repetitive structures of the Arg-Gly-Asp (RGD) or Tyr-Ile-Gly-Ser-Arg (YIGSR) sequence derived from adhesion molecules, and studied their biological characterisation after administration. In the spontaneous metastasis model, multiple intravenous (i.v.) administrations of poly (RGD) and poly (YIGSR) resulted in a reduction of lung tumour colonies, although the monomer peptides, RGD or YIGSR, had no effect under these conditions. The treatment with poly(RGD) substantially prolonged the survival time for mice injected i.v. with B16-BL6 cells as compared to the treatment with RGD and random poly(R, G, D). Tumour cell adhesion to the fibronectin-substrates was remarkably inhibited by adding poly(RGD) freely in solution. Poly(RGD) was found to inhibit completely the ability of platelets to enhance tumour cell adhesion to fibronectin-substrate and tumour cell-elicited platelet aggregation in vitro, but poly(R, G, D) had no such effect. We also found that poly(RGD) led to a decrease in the arrest and retention of tumour cells after its co-injection with radiolabelled tumour cells and that the radiolabelled polypeptide can be at least decomposed into small fragments during circulation. Poly(RGD) was found to be still active in inhibiting experimental lung metastasis even when the contributions of NK cells or macrophages were removed from this system after pretreatment with anti-asialo GM1 serum, 2-chloroadenosine or carrageenan. The results indicate that the poly(RGD)-mediated inhibition of tumour metastasis may be due to the interference of the adhesive interaction of tumour cells with a specific site in the target organs. Derivatives of polypeptides which contain RGD and/or YIGSR sequences derived from cell adhesion proteins may thus provide a promising approach for the control and prevention of cancer metastasis.
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During the metastatic cascade, tumour cells encounter host cells and/or extracellular matrix and basement membrane components (Fidler, 1984) . As a result of adhesive interaction, this encounter may lead to a multicellular embolus formation that includes homotypic or heterotypic cell clumps which can subsequently enhance the survival, arrest and invasiveness of tumour cells (Terranova et al., 1982 (Terranova et al., , 1984 . Such specific interaction is therefore a fundamental event in the metastatic process.
Common or characteristic core sequences in cell adhesion molecules such as fibronectin (Kornblihtt et al., 1985) , vitronectin (Suzuki et al., 1985) and laminin  Sasaki have been found to contribute to cell adhesion, and to the spread or migration of cells (Yamada & Kennedy, 1984; McCarthy & Furcht, 1984; Humphries et al., 1986) . It has been shown that the domain of fibronectin in cellular recognition is carried by an ArgGly-Asp-Ser (RGDS) sequence. The RGD sequence exists commonly in many adhesion molecules (Pierschbacher & Ruoslahti, 1982 . RGD-containing peptides have been shown to promote cell adhesive capability after their surface immobilisation, and to inhibit cell adhesion to fibronectin when added freely in solution (Yamada & Kennedy, 1984 Akiyama & Yamada, 1985) .
Platelets are known to play an important role in the regulation of tumour metastasis (Gasic et al., 1973; Jamieson et al., 1987) . Many different types of tumour cell have been seen to elicit the activation and aggregation of platelets in vitro (Gasic et al., 1973; Pearlstein et al., 1980) . These properties have been correlated with the metastatic potential of tumour cells. Various inhibitors of platelet functions have also been reported to retard tumour metastasis in some tumour models (Kohga et al., 1981; Mussoni et al., 1978; Tsuruo et al., 1985) . We recently reported that ADP (10-6M) induced aggregations of human platelets were inhibited by the pretreatment with poly(RGD) in a concentrationdependent manner, but were not inhibited by treatment with poly (R, G, D) in which three amino acids were randomly arranged and no segment of the RGD sequence was therefore formed . On the other hand, natural killer (NK) cells and macrophages in certain blood cell populations appear to have an important role in the destruction of metastatic tumour cells. The activation of macrophages and NK cells by various immunostimulants led to the reduction of metastatic colonisation (Herberman, 1984; Hanna, 1985; Fidler et al., 1981) .
In this study, we examine the effect of polypeptides containing repetitive structure of the RGD sequence on the lung metastases of tumour cells, and study their biological characterisation in the metastatic cascade in order to gain insight into the mechanism and the action of our selected polypeptide.
Materials and methods

Mice
Specific pathogen-free mice of the inbred C57BL/6 and BALB/c strains, female, 7-10-week-old, were purchased from the Shizuoka Laboratory Animal Centre, Hamamatsu, Japan. Mice were maintained in the Laboratory of Animal Experiments, the Institute of Immunological Science, Hok- kaido University, under laminar air-flow conditions. Cells Highly metastatic Bl 6-BL6 melanoma cells, obtained by an in vitro selection procedure for invasion (Hart, 1979) , were kindly provided by Dr I.J. Fidler (M.D. Anderson Cancer Center, Houston, Tx, USA). B16-BL6 melanoma and Lewis lung carcinoma (3LL) were derived from C57BL/6 mice and a colon 26 carcinoma was derived from BALB/c mice. These cells were maintained as monolayer cultures in Eagle's minimal essential medium (MEM) supplemented with 7.5% fetal bovine serum (FBS), vitamin solution, sodium pyruvate, non-essential amino acid and L-glutamine.
Synthetic polypeptide analogues and other reagents The synthetic polypeptides used in this study and their abbreviations (based on the single-letter amino acid code) are given in Table I . Polypeptides with an Arg-Gly-Asp (RGD) sequence derived from fibronectin or the Tyr-Ile-Gly-SerArg (YIGSR) sequence from laminin, as well as their related analogues, were prepared by the synthesis of the monomer peptide of the RGD or YIGSR sequences by the conventional method and subsequent polymerisation procedures with diphenylphosphoryl azide (DPPA), as described elsewhere (Nishi et al., 1980 (Nishi et al., , 1987 . All the amino acids used in this study were of the L-form. Poly(RGD) or poly(YIGSR) consist of a sequential structure of the RGD or YIGSR sequences respectively, whereas poly(R, G, D) consists of a randomly arranged structure of three amino acids. Hence, in the sequence of poly(RGD), the G residue always lies between the R and D residues, and the -RGDsequence is present as a segment. In the sequence of poly(R, G, D), on the other hand, three amino acids are randomly arranged without rule and the probability of their forming the -RGD-sequence is statistically very small. Copoly(RGD, K) and copoly(RGD, YIGSR) designate the polypeptides randomly arranged by RGD tripeptide and either K or YIGSR respectively, in which -RGD-and/or -YIGSR-sequences are always present as a segment.
Viscometric measurements and SDS-polyacrylamide gel electrophoresis showed that the polypeptides were approximately 10 kDa in average molecular weight. They were then dissolved in Ca2", Mg2 + -free phosphate-buffered saline (PBS). Purified mouse fibronectin was purchased from the Seikagaku Kogyo Co. Ltd (Tokyo, Japan). Arg-Gly-Asp-Ser (RGDS) was purchased from BACHEM Feinchemikauen AG (Switzerland). Pronase P was obtained from Kaken Chemicals Co. Ltd (Tokyo, Japan). All reagents and media used in this study were endotoxin free (approximately < 1.0 ng ml-') as determined by a colorimetric assay (Pyrodick, Seikagaku Kogyo Co., Tokyo, Japan).
Microassay for cell adhesion The adhesion assay was carried out by the method described previously (Saiki et al., 1986 Platelet aggregation Blood was obtained from C57BL/6 mice by puncturing the retro-orbital plexus, using heparin (10 units ml1' in final concentration) as an anticoagulant. Platelet-rich plasma (PRP) was prepared by centrifugation at 160 g for 15 min at room temperature. PRP was adjusted to an appropriate concentration with platelet poor plasma (PPP), which had been prepared by centrifugation at 1,000 g for 10 min. Only plastic tubes and siliconised microcapillaries were used for these procedures. Platelet aggregation was measured in a dual aggregometer Model 440 (Chrono-Log, USA) at 37°C by constant stirring at 1,000 r.p.m. Variable concentrations of B16-BL6 tumour cells suspended in PBS were added to 0.25 ml of PRP which was then preincubated both with and without polypeptides for 5-7 min. The aggregometer was calibrated with PRP to express 100% optical transmission and with PPP to express 0% optical transmission.
Organ distribution and retention of radiolabelled tumour cells B16-BL6 melanoma cells in the exponential growth phase were labelled with '25N-IUdR, as described above. '25I-IUdR- -Arg-Gly-Asp-Arg-Gly-Asp-Arg-Gly-Asp-Arg-Gly-Asp-Arg---
labelled tumour cells (2 x 104) in a volume of 0.2 ml were injected i.v. with or without polypeptide into the lateral tail vein of the C57BL/6 mice. Mice were exsanguinated at times ranging from 30 min to 24 h after the injection. The lungs, liver, spleen, kidneys and blood were collected from each mouse, and rinsed in 70% ethanol. The radioactivity in each organ was measured in a gamma counter.
Labelling of synthetic polypeptide Copoly (RGD, K) was iodinated with Bolton-Hunter reagent according to the conventional procedure. Briefly, 2 mg copoly(RGD, K) was dissolved in 20 pl PBS and added to 1 mCi Bolton-Hunter reagent (N-succinimidyl 3-(4 hydroxy-
propionate, specific activity 2,000 Ci mmol ', New England Nuclear, Boston, MA, USA) freshly dried from a solution in benzene. After agitation of the mixture at 4°C overnight, the reaction was quenched by the addition of 5 pil 1 M glycine in a borate buffer. lodinated polypeptide was separated from the byproducts by gel filtration on a Sephadex G-25 which was equilibrated and eluted with a 0.05 M phosphate buffer (pH 7.5) containing 0.25% (w/v) gelatin. The '25I-labelled polypeptide thus obtained was confirmed by the absorbence at 280 nm in a spectrophotometer.
Statistical analysis
The statistical significance of differences between the groups was determined by applying Student's two-tailed t test unless otherwise mentioned.
Results
Inhibition of spontaneous and experimental lung metastases by polypeptides We first examined the effect of polypeptides containing the RGD and/or YIGSR sequence on lung metastasis of B16-BL6 melanoma in the spontaneous metastasis model (Table   II) . Multiple i.v. administrations of 100 ,.g poly(RGD), poly(YIGSR) or copoly(RGD, YIGSR) significantly reduced the number of lung tumour colonies (P <0.01, 0.05 or 0.001 respectively). Copoly(RGD, YIGSR), in which the RGD and YIGSR sequences were randomly arranged at a 1:1 molar ratio, inhibited tumour metastasis more effectively than either poly(RGD) or poly(YIGSR). We also observed that polypeptides containing RGD sequence inhibited the experimental lung metastases after i.v. co-injection with different original metastatic tumour cells such as B16-BL6 melanoma, 3LL carcinoma and colon 26 carcinoma, but poly(R, G, D), which is a random homologue of poly(RGD), did not b, c). The survival rate of mice given i.v. injections of B16-BL6 melanoma cells admixed with poly(RGD), poly (R, G, D) (Habu et al., 1981) and 2-chloroadenosine (Saito & Yamaguchi, 1985) , and carrageenan were macrophage toxic substances. Table III shows that the pretreatments with antiasialo GM 1 serum, 2-chloroadenosine or carrageenan enhanced the frequency of experimental metastasis as compared with the frequency found among untreated normal mice. The co-injection with poly(RGD) led to a significant reduction of lung tumour colonies in both untreated and treated mice.
Effect ofpoly (RGD) on the interaction between tumour cells and platelets Several investigators have reported that platelets play an important role in the regulation of metastatic seeding. We therefore examined the effect of platelets and/or poly(RGD) on tumour cell adhesion to fibronectin-coated substrates. Figure 2 shows that B16-BL6 cells attached themselves to the fibronectin-coated substrate, but poly(RGD) led to a significant inhibition of tumour cell-adhesion to the substrate (P <0.001). On the other hand, PRP dramatically enhanced the adhesion of B16-BL6 cells to the fibronectin-substrate in an assay on only 10 min, whereas PPP did not. The enhanced adhesion of tumour cells in the presence of PRP was dramatically inhibited by the addition of poly(RGD). These results indicate that poly(RGD) is able to inhibit the adhesion of tumour cells to immobilised fibronectin, as well as cell adhesion enhanced by platelets. We also investigated the effect of poly(RGD) on the platelet aggregation induced by tumour cells in vitro. Platelet aggregation elicited by B16-BL6 cells was monitored by a dual aggregometer (Figure 3 ). Poly(RGD) at a concentration of 100 tgml-' inhibited the platelet aggregation induced by B16-BL6 cells. In contrast, poly (R, G, D) , in which three amino acids are randomly arranged, was not able to suppress the aggregation. Typical heterotypic cell aggregations between B16-BL6 cells and platelets, or the aggregation between platelets themselves, were microscopically observed after their co-incubation for 30 min (Saiki et al., 1989 a) . The cell aggregations were completely inhibited by the addition of 200 gig ml-' poly(RGD) but not by the addition of poly(R, G, D). These results clearly indicated that the adhesive interactions between tumour cells and platelets or between platelets on their own were completely inhibited by poly(RGD). Table  IV . Significantly lower values were found in the lungs of mice at 4 and 24 h after the co-injection with poly(RGD). However, there are no discernible differences between control and poly(RGD) injected mice in the arrest and retention of labelled tumour cells in liver, spleen, kidneys and blood after tumour injection (data not shown).
Clearance of '25"-labelled polypeptide We recently found that the clearance of '251I-labelled poly(RGD, K) in the circulation was biphasic and rapid at an early phase after the i.v. injection (Saiki et al., 1989 b) .
We next investigated the possibility that the polypeptide can be decomposed to by-products in the circulation. Figure 4 shows the separation patterns of the polypeptide by chromatography. Analysis of the column eluate revealed a main peak of radioactivity of untreated '251I-labelled poly(RGD, K) in the void volume. This main peak of 125I-labelled polypeptide was observed to decrease as a result of either the treatment with 75% fresh mouse serum or I mg ml-' pronase, and a new broad peak generated around the fraction number 27. In contrast, polypeptide treated with heat (56°C, 30 min) inactivated serum showed a similar -: X. eluting pattern to untreated polypeptide. This result indicates that '251I-labelled polypeptide can be decomposed into small molecular weight fragments by a serum or pronase treatment in vitro.
Discussion
Since the adhesive interactions between tumour cells and host cells or components of extracellular matrix play a crucial role in the progress of tumour metastases throughout a series of complex events, several attempts have been made to control the mechanisms involved in tumour cell adhesion during the metastatic cascade. In a previous report (Barsky et al., 1984) , the co-injection of tumour cells with purified laminin followed by i.v. injection enhanced pulmonary metastasis, whereas an enzymatic fragment of laminin inhibited the metastasis. Recently, synthetic oligopeptides containing characteristic sequences in cell-binding domains of adhesion molecules (GRGDS derived from fibronectin (Humphries et al., 1986 (Humphries et al., , 1988 or YIGSR derived from laminin (Iwamoto et al., 1987) ) have been shown to inhibit lung metastases when co-injected i.v. with metastatic tumour cells. We have synthesised some original polypeptides consisting of the repetitive structure of a common core sequence in cell adhesion molecules, such as poly(RGD) or poly(YIGSR), and found that these polypeptides are able to inhibit experimental lung metastases of B16-BL6 melanoma cells more effectively than such oligopeptides as RGD, RGDS or YIGSR on a weight basis (Saiki et al., 1989 c) . Furthermore, intratumoural or intravenous administrations of poly(RGD) into tumour-beaning mice (in a spontaneous metastasis model) resulted in a striking reduction of lung tumour colonies (Saiki et al., 1989 b) .
To extend our previous work on the inhibition of lung metastasis of tumour cells by a polypeptide containing RGD sequence, we here examine the inhibitory effect of the polypeptides on lung metastasis of tumour cells and their biological characterisation after the administration. Multiple i.v. administrations of poly(RGD), poly(YIGSR) or their hybrid polypeptide copoly (RGD, YIGSR) resulted in the reduction of lung tumour colonies (Table II) , but did not affect the primary tumour size at the time of tumour excision (data not shown). The co-injection of B16-BL6 melanoma cells with poly(RGD) significantly enhanced the survival rate as compared with untreated control, poly(R, G, D) or RGD (Figure 1 ). These results indicate that derivatives of RGDand/or YIGSR-containing polypeptides may be potentially useful in the prevention of cancer metastasis.
Once in circulation, metastatic tumour cells encounter various host cells or components (Fidler, 1984 (Pearlstein et al., 1980) . The adhesive interaction between tumour cells and/or platelets may form homotypic or heterotypic cell clumps and aggregations which can subsequently be arrested and extravasated (Terranova et al., 1982 (Terranova et al., , 1984 . Such interactions may also lead to an enhancement and stabilisation of tumour cell arrest in capillary vessels by increasing the size of tumour cell emboli as well as by shielding the tumour cells from immune response. As shown in Figure 3 , tumour-induced platelet aggregation was completely inhibited by adding poly(RGD) but not by unrelated random polypeptide, poly (R, G, D) . In addition, poly(RGD) also inhibited the adhesion of B16-BL6 cells to fibronectin-coated substrate (Figure 2) . We have recently reported that the peptides or polypeptides containing the RGD sequence, when added freely in solution, are able to inhibit the tumour cell adhesion to fibronectin substrate, while unrelated peptides such as Arg-Gly-Glu-Ser (RGES) or His-Gly-Gly (HGG) are not able to do this (Saiki et al., 1989 b) . These results clearly demonstrate that the cell adhesioninhibiting activities of poly(RGD) depend on a specific (Cheresh et al., 1987; Wewer et al., 1987) . Tumour cell adhesion to fibronectin was enhanced remarkably in the presence of platelets (Figure 2 ). It has been reported that the mechanism by which platelets enhance tumour cell adhesion to the subendothelial matrix is mediated by surface contact between tumour cells and platelets, and depends on a platelet membrane component and cytoskeleton (Menter et al., 1987) . During the metastatic process, tumour-induced platelet aggregation may provide an additional means of adhesion through the interaction of platelets with adhesion proteins such as fibrinogen and fibronectin, as well as the opportunity to consolidate the adhesion through a thrombotic formation caused by platelet activation and the deposition of fibrin. Poly(RGD) completely inhibited the platelet-enhanced adhesion of B16-BL6 cells to the fibronectin substrate (Figure 2 ). RGD-containing peptides have been shown to inhibit the interaction of adhesive protein such as fibrinogen, fibronectin and the von Willebrand factor with a platelet membrane, presumably by means of the glycoprotein complex Ilb/Illa which serves as a receptor on platelets for such adhesive proteins (Haverstick et al., 1985; Plow et al.,1987) . A lIb/Illa-like-glycoprotein identified on endothelial cells may also serve as a matrix receptor (Charo et al., 1986; Fitzgerald et al., 1985) . Thus the inhibition of platelet aggregation and platelet-enhanced tumour cell adhesion to fibronectin substrate by poly(RGD) strongly implicates that the RGD sequence competitively blocks any interaction between tumour cells, tumour-stimulated platelets (presumably the lIb/Illa complex) and such adhesive proteins as fibrinogen and fibronectin. Further studies will be needed to determine these points.
To investigate the effect of poly(RGD) on the arrest and lodgement of tumour cells in organs, we examined the organ retention of radiolabelled B16-BL6 cells. The co-injection of the tumour cells with poly(RGD) led significantly to a reduced arrest of tumour cells in the lung at 4 and 24 h after the injection (Table IV) . The inhibition of lung colonisation by poly(RGD) may therefore depend on the decrease in the arrest and retention of tumour cells in the lung as a result of the inhibition of the adhesive interaction. We recently reported that radiolabelled polypeptide was biphasically cleared out from the circulation by the i.v. injection. The respective half-life of polypeptide at early and late phase was approximately 15min and 6h (Saiki et al., 1989 b) . These results indicate that this polypeptide may promote cell loss from the lung over 24 h after the co-injection with tumour cells.
Poly(RGD) significantly inhibited the experimental lung metastasis in mice pretreated with anti-asialo GM1 serum, 2-chloroadenosine or carrageenan as well as untreated mice (Table III) . Since poly(RGD) was still active when the contributions of NK cells and macrophages were removed from our system, its inhibitory mechanism is likely to be unrelated to the stimulation and activation of these cells. The poly(RGD) used did not affect direct cytotoxicity against a variety of cell, nor did it affect their cell growth and the aggregation of serum proteins (unpublished data).
In conclusion, we here indicate that a unique RGDcontaining polypeptide can dramatically inhibit lung metastases in experimental and spontaneous metastases models by means of its ability to interfere with the cellular adhesive process of metastases. The survival rate of mice receiving tumour cells admixed with poly(RGD) was virtually enhanced relative to control groups. Poly(RGD) inhibited the ability of platelets to enhance the adhesion of tumour cells, and also led to a decrease in the arrest and retention of tumour cells in the lung after co-injection with tumour cells. A polypeptide containing a core sequence derived from cell adhesion molecules may thus provide a promising approach for a therapy in the control of cancer metastases. 
